No abstract

Aim. To evaluate the expression level and prognostic significance of androgen in primary operable luminal breast cancer without overexpression of Her2/neu in postmenopausal women. Methods. We analyzed treatment outcomes of 60 cases of primary operable (T1-2N0M0) luminal breast cancer without overexpression of Her2/neu in postmenopausal women. The follow-up period was 5 years. All cases were divided by immunohistochemical method into luminal A (20 females) and luminal B (40 patients) subtypes. Along with the standard panel of immunohistochemical markers, expression of nuclear androgen receptors was measured in tumor tissues of all patients. Depending on the expression levels, patients with luminal A and B subtypes were divided into three groups: (1) with high, (2) moderate and (3) low or negative expression. Results. Mean levels of androgen receptor expression in the nuclei of tumor cells in patients with luminal A subtype (57.3±5.9%) were higher than those of luminal B subtype (21.4±4.04%) by 62.7% (Mann-Whitney test, р=0.0026). In patients with luminal A subtype, the maximal accumulation of androgen receptors in the nuclei of tumor cells was 2.7 times higher (р=0.0023) than in patients with luminal B subtype. All cases diagnosed with the disease progression were characterized by low or negative level of nuclear androgen receptor expression. Conclusion. Negative and low levels of androgen receptor expression in tumor tissues of postmenopausal patients with luminal primary operable breast cancer without overexpression of Her2/neu might be an independent factor associated with poor prognosis.

At present, to develop new, scientifically justified, technologiesof an accompanying therapy to improve the oncological situationis a challenge to health care. A therapy to accompany aspecific cancer treatment in case of a malignant process in anorganism is dictated by the necessity to raise the nonspecific resistanceof the organism in cancer patients. In this case, originalmethodological approaches to initiate the mechanisms of thenonspecific resistance have been developed on the basis of thetheory of the adaptational reactions. Within the framework ofthe above theory, some concepts of relationship between thespecific and nonspecific anti-tumor processes have been extensivelydeveloped that may be successfully applied to solvingtasks of the National Health Care Program.Aim. The aim hereof is to introduce the theoretical basics ofthe nonspecific adaptation regulation and control by a tumor-bearing organism into practice for an integrated treatmentof malignant tumors with the use of the activation therapy technologies.Materials and methods. Our research work has involvedclinical data on 1310 patients, who have been diagnosedwith cancer of different localization: breast cancer (n = 170),cervical cancer (n = 60), lung cancer (n = 760), bladder cancer(n = 120), brain gliomas of high grade of malignancy andmetastatic damage (n = 170) and extended colorectal cancer(n = 30) and who have completed their treatment at the NationalMedical Research Centre of Oncology of the Ministry ofHealth of the Russian Federation.

No abstract

No abstract